Compare SkyWest Inc (SKYW) vs Viatris Inc (VTRS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
SkyWest Inc vs Viatris Inc — how do they compare? SkyWest Inc trades at $95.26 (market cap $3.94B), while Viatris Inc trades at $17.54 (market cap $19.79B). The key difference: Viatris Inc is far larger — about 5× SkyWest Inc's market cap, and Viatris Inc pays a 2.83% dividend while SkyWest Inc pays none. Which is the better fit depends on your goals.
| SKYW | VTRS | |
|---|---|---|
Market Cap | $3.94B | $19.79B |
Sector | Technology | Health |
52-Week High | $123.72 | $17.39 |
52-Week Low | $78.40 | $8.74 |
Enterprise Value | $5.79B | $32.00B |
Dividend Yield | — | 2.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SkyWest (SKYW) trades at $99.34, up 2.17% with a bullish technical signal. The stock shows strong fundamentals with a P/E of 9.52 and net income margin of 10.42%. Recent earnings beat expectations in Q1 2026, and analyst consensus is a buy with a $109.33 price target. The company announced a new president and COO in July 2026, signaling operational focus amid industry fuel cost pressures.
The outlook is positive given undervaluation and earnings momentum, but risks include elevated jet fuel expenses impacting airline profitability. Investor sentiment is supported by institutional buying and lack of sell ratings, though macroeconomic headwinds remain a key watchpoint for near-term performance.
Viatris (VTRS) trades at $17.59, up 1.74% today, with a bullish technical signal and consistent earnings beats in recent quarters. The company reported revenue of $14.3B for 2025 but posted a net loss of $3.51B, reflecting margin pressures. Positive pipeline developments include FDA acceptance of a new drug application for fast-acting meloxicam, with a PDUFA date set for December 2026. Cash flow from operations remains strong at $2.32B, supporting debt reduction efforts.
The outlook is mixed: analyst consensus targets $20.00 (13.7% upside), but profitability challenges and high debt levels pose risks. Investment appeal hinges on successful pipeline execution and margin recovery, while competitive and regulatory pressures in the generics market remain key watchpoints for shareholders.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About SkyWest Inc
SkyWest, Inc. is a major North American regional airline company, operating primarily through its subsidiary, SkyWest Airlines. The company provides regional airline service to various large airlines under contract, including United Airlines (as United Express), Delta Air Lines (as Delta Connection), American Airlines (as American Eagle), and Alaska Airlines (as Alaska SkyWest). SKYW's primary business is providing essential flight services, connecting smaller cities to major airline hubs across the United States.
Read more on SKYW →About Viatris Inc
Formed by the combination of Mylan and Pfizer's Upjohn business in 2020, Viatris is one of the world's largest generic drug manufacturers, with a substantial off-patent branded drug portfolio. Its portfolio consists of more than 1,400 molecules with penetration across most of the developed world and in select emerging markets. The company's branded drug portfolio consists of off-patent blockbuster drugs that continue to generate strong sales, including Lipitor, Norvasc, Lyrica, Viagra, and EpiPen. While global competition has facilitated the commodification of small-molecule generic drugs, the company has demonstrated an edge over peers in its ability to manufacture complex generics (for example, generic Advair and Copaxone).
Read more on VTRS →
